Open Pilot Trial of Adapted Cognitive Processing Therapy for Comorbid PTSD and Opioid Use Disorder (OPTIMO)
Onsite PTSD Treatment to Improve MOUD Outcomes: Open Pilot Trial of Stakeholder-engaged Adapted Cognitive Processing Therapy
The goal of this open pilot trial is to learn if an adapted version of Cognitive Processing Therapy (CPT), delivered through telehealth, can treat posttraumatic stress disorder (PTSD) in adults who use syringe services programs. The main questions it aims to answer are:
- Can the intervention be done in syringe services programs?
- Are syringe services program clients and staff open to the intervention?
- Can the intervention lower PTSD symptoms and help participants keep taking their medication for opioid use disorder (ex. Buprenorphine or methadone)?
Participants will:
- Attend 4-18 tele-delivered CPT sessions at the syringe services program
- Complete between-session CPT practice with the support of SSP-based "coaches"
- Meet with research staff monthly to complete surveys of their PTSD symptoms, drug use, and mental health
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Teresa Lopez-Castro, PhD
- Phone Number: 646-745-7123
- Email: tlopezcastro@ccny.cuny.edu
Study Contact Backup
- Name: Aaron D Fox, MD
- Phone Number: 718-920-7173
- Email: adfox@montefiore.org
Study Locations
-
-
New York
-
New York, New York, United States, 10035
- OnPoint
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Over the age of 18
- Regular syringe services program attendance (ex. at least 4 visits in the past month)
- Meeting DSM-5 opioid use disorder criteria
- Having been prescribed a medication for opioid use disorder in the past 30 days at the time of screening
- Criterion A event as measured by the Life Events Checklist for DSM-5 (LEC-5)
- PTSD symptoms at the level of a PTSD diagnosis as evidenced by a score of 31 or greater on the PTSD Checklist for DSM-5 (PCL-5)
- Ability to understand English
- Consent to have assessment interviews audio recorded and teletherapy sessions video recorded for research purposes
- Ability to provide informed consent
Exclusion Criteria:
- High risk for suicidal thoughts and/or behaviors that would make participation dangerous, as measured by the Columbia Suicide Severity Rating Scale Lifetime-Recent Screen
- Meeting DSM-5 criteria for a current psychotic or bipolar disorder.
- Cognitive impairment liable to interfere with completion of study procedures
- Currently receiving trauma-focused psychotherapy (i.e. Prolonged Exposure, Cognitive Processing Therapy).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Adapted Cognitive Processing Therapy
Participants will receive 4-18 sessions of telehealth-delivered Cognitive Processing Therapy (CPT) adapted for people who use syringe services programs.
Participants will attend the 50-minute CPT sessions in a private space within the syringe services program.
|
Cognitive Processing Therapy (CPT) is an evidence-based psychotherapy for PTSD that provides education and teaches skills to challenge the trauma-related beliefs that maintain PTSD symptoms.
In this study, CPT has been adapted to include content on the relationship between substance use and PTSD and a focus on harm reduction.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Eligible Participants
Time Frame: Baseline
|
Proportion of persons eligible to enroll in the study of all possible SSP clients approached during 6-month recruitment period.
Assessed using count data of individuals failing screen.
|
Baseline
|
|
Proportion of Eligible Participants who Enroll
Time Frame: Week 1
|
Proportion of all eligible persons who enroll.
Assessed using count data of individuals consented.
|
Week 1
|
|
Mean Number of Intervention Sessions Attended
Time Frame: Up to Week 12
|
Mean number of teletherapy sessions attended by enrolled participants.
Assessed using count data of session attendance.
|
Up to Week 12
|
|
Proportion of Study Visits Completed by Enrolled Participants
Time Frame: Week 12
|
Proportion of study visits completed by enrolled participants.
Assessed using count data of study visit attendance.
|
Week 12
|
|
Proportion of Participants With at Least one SSP-based Coach Encounter
Time Frame: Week 12
|
Proportion of participants who have attended at least one teletherapy sessions and have had at least one SSP-based coach encounters.
|
Week 12
|
|
Participant-rated Client Satisfaction Questionnaire Score
Time Frame: Week 12
|
8-item, participant-rated assessment of satisfaction with intervention.
Total score is the sum of responses and ranges from 8 to 32.
Higher scores indicate greater client satisfaction and treatment acceptability.
|
Week 12
|
|
Therapist & Coach-Rated Feasibility of Intervention Measure Score
Time Frame: Week 12
|
Four-item, clinician-rated assessment of the feasibility of the intervention.
Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20.
Higher scores indicate greater clinician-rated feasibility.
|
Week 12
|
|
Therapist & Coach-Rated Acceptability of Intervention Measure Score
Time Frame: Week 12
|
Four-item, clinician-rated assessment of the acceptability of the intervention.
Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20.
Higher scores indicate greater clinician-rated acceptability.
|
Week 12
|
|
Therapist & Coach-Rated Intervention Appropriateness Measure Score
Time Frame: Week 12
|
Four-item, clinician-rated assessment of whether the intervention is appropriate for the setting and target population.
Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20.
Higher scores indicate greater clinician-rated appropriateness.
|
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in PCL-5 Total Score
Time Frame: Baseline and Week 12
|
The PCL-5 has 20 items assessing PTSD symptom severity.
Total scores range from 0-80 with higher scores indicating more severe PTSD symptoms.
The score at baseline will be subtracted from the score at week 12.
|
Baseline and Week 12
|
|
Changes from baseline in self-reported past 30-day use of prescribed MOUD
Time Frame: Baseline and Week 12
|
Number of self-reported days in the past 30 days in which prescribed MOUD was taken.
The number at baseline will be subtracted from the number at week 12.
|
Baseline and Week 12
|
|
Changes from baseline in self-reported days of nonprescribed opioids
Time Frame: Baseline and Week 12
|
Number of self-reported days of nonprescribed opioids in past 30 days using the Drug Use section of the Addiction Severity Index.
The number at baseline will be subtracted from the number at 12 weeks.
|
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Teresa Lopez-Castro, PhD, The City College of New York, CUNY
- Principal Investigator: Aaron D Fox, MD, Albert Einstein College of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB# 2025-16601
- R61DA059032 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.